Aerocrine listed on the Stockholm Stock Exchange
Aerocrine AB, part of CapMan's Swedestart Life Science fund portfolio will today be listed on the Stockholm Stock Exchange with the ticker AERO.
Swedestart Life Science fund did not sell its Aerocrine shares in connection with the IPO but holds approx. 6 per cent of the company’s shares. The shares are subject to a 12-month lock-up period. Other investors include HealthCap, H&B, Investor and Scandinavian Life Science Venture.
Aerocrine AB, a Swedish medical technology company founded in 1997, develops and commercialises products for improved management and care of asthma. The NIOX monitoring devices developed by Aerocrine measure the nitrogen content of the patient’s exhaled breath for the diagnosis and control of airway inflammation. Until now, routine assessment of airway inflammation has not been possible. The NIOX and NIOX MINO devices are designed for use in both clinical settings and the home. Asthma is a growing global health problem and it is now estimated that as many as 300 million people suffer from asthma worldwide.
The objective of the IPO is to expand Aerocrine’s ownership base and to create prerequisites for future value creation and continuity of business operations.
CapMan Life Science invested in Aerocrine in 2005 and the company has shown good development during the investment period. Aerocrine’s IPO does not have an impact on CapMan Plc’s result for 2007.
Read more
| Fund | CapMan Life Science IV |
| Portfolio Company | Aerocrine |
| Date of Transaction | 2007-06-15 |
| Transaction | IPO |
| Seller | CapMan Life Science IV |
| Buyer | |
| Size of Transaction | SEK 1,150.0m |
| Ind. Focus | Life Science |
| Geography | Sweden |
| Stage | Venture |